Polycystic ovary syndrome (PCOS) affects approximately 10% of South African women of reproductive age — making it one of the most common hormonal conditions our doctors encounter. Many of these women share the same frustrating experience: they gain weight easily, lose it with enormous difficulty, and find that standard advice ("eat less, move more") simply doesn't work the way it does for everyone else. GLP-1 medications are changing this picture significantly — and here's what the evidence actually shows.
Why PCOS is different: The most common form of PCOS involves underlying insulin resistance — the same metabolic mechanism that drives type 2 diabetes. This is why GLP-1 medications, which directly target insulin resistance and appetite, are particularly well-suited to PCOS management. It's not a coincidence that many PCOS patients find GLP-1 therapy works dramatically better than other weight loss approaches they've tried.
To understand why GLP-1 works for PCOS, you need to understand the core biology of the condition. In most PCOS patients, the underlying driver is insulin resistance — the cells don't respond efficiently to insulin, so the pancreas overproduces it to compensate. This excess insulin does two things relevant to PCOS:
GLP-1 medications break this cycle by directly improving insulin sensitivity, reducing insulin secretion, and promoting significant weight loss. The result: lower circulating insulin → less ovarian androgen stimulation → improved PCOS symptoms.
Even modest weight loss of 5–10% of body weight restores menstrual regularity in approximately 30% of anovulatory PCOS patients. GLP-1 medications produce far more than this — semaglutide (STEP trials) produces ~15% weight loss; tirzepatide (SURMOUNT trials) produces ~20–22%. This level of weight loss can produce dramatic improvements in PCOS symptom burden.
Beyond weight loss, GLP-1 medications have direct effects on insulin signalling. Several studies show reduced fasting insulin and HOMA-IR scores (insulin resistance markers) in PCOS patients on GLP-1 therapy, beyond what would be expected from weight loss alone. This directly reduces the androgen-driving insulin excess.
Multiple studies and case series report restored ovulation and menstrual regularity in anovulatory PCOS patients on GLP-1 therapy. The mechanism is primarily via improved insulin sensitivity and weight loss — both of which reduce the hypothalamic-pituitary disruption that drives anovulation in PCOS.
Several small trials have shown reductions in free testosterone and total androgen levels in PCOS patients on GLP-1 therapy. This correlates with improvements in hirsutism, acne, and androgenic alopecia in some patients — though these symptoms typically take 6–12 months to show visible improvement even after hormonal normalisation.
PCOS has a significant inflammatory component. GLP-1 medications have demonstrated direct anti-inflammatory effects — reducing CRP and other inflammatory markers — beyond their weight and insulin effects. This may contribute independently to the symptom improvement seen in PCOS patients.
| Factor | Metformin | GLP-1 (Ozempic/Mounjaro) |
|---|---|---|
| Weight loss | Minimal (1–3%) | Substantial (15–22%) |
| Insulin sensitisation | Good | Good + additional mechanisms |
| Cycle restoration | Modest | Significant (via weight + insulin) |
| Side effects | GI (diarrhoea, nausea) | GI (nausea, early phase) |
| Cost in SA | Very low (generic) | Moderate–high |
| Route | Daily oral tablet | Weekly injection |
| Combination use | Yes — often combined | Yes — complementary |
For PCOS patients with a significant weight component (BMI ≥27–30), GLP-1 therapy substantially outperforms metformin on the outcomes most patients care about most. For lean PCOS with primary menstrual irregularity and no significant weight component, metformin remains the cost-effective first-line approach.
In South Africa, GLP-1 medications are prescribable for PCOS patients who meet the standard weight management criteria:
This means PCOS patients with BMI as low as 27 are eligible for GLP-1 therapy, making it accessible to a wide range of PCOS phenotypes — not just those with severe obesity.
Important: GLP-1 medications are contraindicated in pregnancy and must be stopped before attempting conception. If you're planning a pregnancy, discuss timing and a transition plan with your doctor before starting treatment.
At your consultation, make sure to mention:
Our doctors have experience managing PCOS with GLP-1 therapy. Book an online consultation — 15 minutes, 100% private. R700 first visit.
Book Consultation — R700